Gottlieb, McClellan: Incentivize Use Of RWE To Back COVID-19 Therapies

In a Wednesday (May 20) report, former FDA chiefs Mark McClellan and Scott Gottlieb call for increased funding and incentives to encourage collection and use of real-world evidence for COVID-19 therapies that make it to market through Emergency Use Authorization or FDA approval. RWE will play a major role in filling key evidence gaps and answering questions about cost effectiveness that might exist for marketed COVID-19 therapies, especially those that come to market through emergency authorization before trials are complete,...